Laurus Labs logo

LAURUSLABS - Laurus Labs Share Price

₹468.05 -16.6  -3.4%

Last Trade - 14/05/21

Mid Cap
Market Cap £2.43bn
Enterprise Value £2.56bn
Revenue £466.3m
Position in Universe 161st / 3111
Unlock LAURUSLABS Revenue
Relative Strength (%)
1m +4.93%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -7.16%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Mar 2016 2017 2018 2019 2020 2021 2022E 2023E CAGR / Avg
18,110 19,315 20,690 22,919 28,317 48,135 57,669 67,742 +21.6%
+95.4 +65.1 -24.5 -44.3 +172.6 +281 +13.4 +15.7
Balance Sheet
FINANCIAL BRIEF: : For the fiscal year ended 31 March 2021, Laurus LabsLtd revenues increased 70% to RS48.14B. Net incomeincreased from RS2.55B to RS9.84B. Revenues reflect anincrease in demand for the Company's products and servicesdue to favorable market conditions. Dividend per shareincreased from RS0.50 to RS2.00. Basic Earnings per Shareexcluding Extraordinary Items increased from RS4.79 toRS18.36.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for LAURUSLABS
Graphical History



Net Income


Normalised EPS


PE Ratio Range


Dividend Yield Range

LAURUSLABS Dividend Yield Range Unlock LAURUSLABS Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
Profile Summary

Laurus Labs Limited is an India-based manufacturer of active pharmaceutical ingredietns (APIs) for anti-etrovirals (ARVs), oncology, cardiovascular, anti-diabetics, anti-asthma and gastroenterology. The Company develops and manufactures oral solid formulations, provides contract research and manufacturing services (CRAMS) and contract development and manufacturing organization (CDMO) to the global pharmaceutical companies. The Company also produces specialty ingredients for nutraceuticals, dietary supplements, and cosmeceuticals. Its business units include Generics APIs, Generics Finished Dosage Forms (FDFs) and Synthesis/Ingredients. The Generics APIs business comprises the development, manufacture and sale of APIs and advanced intermediates in the ARV, Hepatitis C, oncology, cardiovascular, anti-diabetic, anti-asthmatic, gastroenterology and ophthalmic therapeutic areas. The Generics FDFs is engaged in developing and manufacturing oral solid formulations.

Last Annual March 31st, 2021
Last Interim March 31st, 2021
Incorporated September 19, 2005
Public Since December 19, 2016
No. of Shareholders: n/a
No. of Employees: 3,789
Sector Healthcare
Industry Pharmaceuticals
Exchange National Stock Exchange of India
Shares in Issue 536,602,385
Free Float (0.0%)
Eligible for
LAURUSLABS Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for LAURUSLABS
Upcoming Events for LAURUSLABS
Friday 9th July, 2021 Estimate
Laurus Labs Ltd Annual Shareholders Meeting
Thursday 15th July, 2021
Laurus Labs Ltd Annual Shareholders Meeting
Frequently Asked Questions for Laurus Labs
What is the Laurus Labs share price?

As of 14/05/21, shares in Laurus Labs are trading at ₹468.05, giving the company a market capitalisation of £2.43bn. This share price information is delayed by 15 minutes.

How has the Laurus Labs share price performed this year?

Shares in Laurus Labs are currently trading at ₹468.05 and the price has moved by 0.433k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Laurus Labs price has moved by 0.231k% over the past year.

What are the analyst and broker recommendations for Laurus Labs?

Of the analysts with advisory recommendations for Laurus Labs, there are there are currently 3 "buy" , 0 "hold" and 2 "sell" recommendations. The overall consensus recommendation for Laurus Labs is Hold. You can view the full broker recommendation list by unlocking its StockReport.

When will Laurus Labs next release its financial results?

Laurus Labs is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2022-03-31
What is the Laurus Labs dividend yield?

The Laurus Labs dividend yield is 0.43% based on the trailing twelve month period.

Does Laurus Labs pay a dividend?

Last year, Laurus Labs paid a total dividend of 2, and it currently has a trailing dividend yield of 0.43%. Looking ahead, Laurus Labs has not announced an ex-dividend date yet and the next dividend pay date is 2021-05-19.

When does Laurus Labs next pay dividends?

Laurus Labs has yet to annouce their ex-dividend date and the next dividend pay date is 2021-05-19. The historic dividend yield on Laurus Labs shares is currently 0.43%.

How do I buy Laurus Labs shares?

To buy shares in Laurus Labs you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Laurus Labs?

Shares in Laurus Labs are currently trading at ₹468.05, giving the company a market capitalisation of £2.43bn.

Where are Laurus Labs shares listed? Where are Laurus Labs shares listed?

Here are the trading details for Laurus Labs:

Country of listing: India
Exchange: NSI
Ticker Symbol: LAURUSLABS
What kind of share is Laurus Labs?

Based on an overall assessment of its quality, value and momentum, Laurus Labs is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Laurus Labs share price forecast 2021?

Shares in Laurus Labs are currently priced at ₹468.05. At that level they are trading at 0.77% premium to the analyst consensus target price of 0.00.

Analysts covering Laurus Labs currently have a consensus Earnings Per Share (EPS) forecast of 20.736 for the next financial year.

How can I tell whether the Laurus Labs share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Laurus Labs. Over the past six months, the relative strength of its shares against the market has been 39.63%. At the current price of ₹468.05, shares in Laurus Labs are trading at 42.98% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Laurus Labs PE Ratio?

The Laurus Labs PE ratio based on its reported earnings over the past 12 months is 25.6. The shares are currently trading at ₹468.05.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of Laurus Labs?

Laurus Labs's management team is headed by:

Satyanarayana Chava - CEO
GSR Anjaneyulu - EVP
Martyn James Peck - SVP
V. Uma Maheswer Rao - EVP
Ravikumar V - CFO
Chandrakanth Chereddi - EDR
Aruna Bhinge - NID
Rajesh Chandy - NID
Lakshmana V - SVP
M. Bhaskaraiah - SVP
Srinivasa S - SVP
G. Venkateswar Reddy - GMG
M.Venu Gopala Rao - NEC
Ravindranath Kancherla - NID
Who are the major shareholders of Laurus Labs?

Here are the top five shareholders of Laurus Labs based on the size of their shareholding:

Chava (Satyanarayana) Individual Investor
Percentage owned: 16.58% (89.0m shares)
Chava (Nagarani) Individual Investor
Percentage owned: 6.55% (35.1m shares)
Amansa Holdings Pvt Ltd Corporation
Percentage owned: 5.04% (27.1m shares)
Raju (Shrihari Kaldindi) Individual Investor
Percentage owned: 4% (21.5m shares)
Kalidindi (Raju Srihari) Individual Investor
Percentage owned: 3.26% (17.5m shares)
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.